Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and U...
September 23 2020 - 8:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced the launch
of its “Forward for Health Equity” grant program. The program will
provide funding to nonprofit healthcare organizations with
innovative projects focused on improving healthcare access, with an
initial focus on reducing racial disparities in prostate cancer and
uterine fibroids in the U.S. Myovant will award as many as four
grants of up to $50,000 each, for a total of $200,000.
Prostate cancer is the second deadliest cancer in men in the
U.S. and has the largest racial disparity of any major cancer,
killing Black men twice as often as white men. Uterine fibroids can
cause debilitating symptoms such as heavy menstrual bleeding and
pain, leading to over 250,000 hysterectomies each year in the U.S.,
with Black women more likely to undergo more invasive surgical
procedures. Studies have also shown that Black men and women have
less access to healthcare, and access issues such as lack of
insurance coverage have been shown to contribute to the racial
disparities in prostate cancer and uterine fibroids.
“Myovant is committed to redefining care for women and for men,
not only through the development of new medicines but also through
initiatives that aim to address the broader societal issues that
lead to health inequities,” said Jarrad Aguirre, M.D., head of
corporate strategy and advocacy at Myovant Sciences. “We have
forged multiple cross-sector partnerships to advocate for a world
in which everyone can move forward on their journey with confidence
and health, and we are proud to expand our commitment with the
launch of the Forward for Health Equity grant program.”
Myovant previously launched the Female Forward Together
coalition in partnership with Evidation Health, Flo Health,
HealthyWomen, and PERIOD, with coalition projects including the
development of a digital tool to evaluate menstrual blood loss and
the creation of a storytelling initiative to reduce stigma around
menstruation. Myovant also recently launched the Forward Momentum
coalition in partnership with BlackDoctor.org, Evidation Health,
and Movember to improve representation of Black men and women in
research studies and to develop digital tools for men with prostate
cancer.
“Prostate cancer and uterine fibroids have a disproportionate
impact on Black men and women, and studies have shown those
populations may experience worse outcomes from these diseases due
to societal inequities and disparities in healthcare access,” said
Reggie Ware, chief executive officer of BlackDoctor.org. “These
disparities have been exacerbated by the COVID-19 pandemic, making
an effort like Myovant’s Forward for Health Equity grant program an
urgent priority and an important initiative.”
The “Forward for Health Equity” grant program will accept
applications through December 31, 2020. Applicants must be
U.S.-based nonprofit healthcare organizations. Applicants may not
be individual healthcare professionals. Applications will be
evaluated based on 1) greatest potential to improve health equity,
2) degree of innovation, and 3) focus on healthcare access.
Applications will be reviewed by a committee consisting of Myovant
employees and external leaders and advocates.
For more information on how to apply, please contact
forwardforhealthequity@myovant.com.
About Myovant Sciences Myovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Our lead product candidate, relugolix, is
a once-daily, oral GnRH receptor antagonist. Relugolix combination
tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone
acetate 0.5 mg) is under regulatory review in Europe and
the U.S. for women with uterine fibroids and is under
development for women with endometriosis. Relugolix monotherapy
tablet (120 mg) is under regulatory review in
the U.S. for men with advanced prostate cancer. We are
also developing MVT-602, an oligopeptide kisspeptin-1 receptor
agonist, which has completed a Phase 2a study for female
infertility as part of assisted reproduction. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon
Pharma Co., Ltd., is our majority shareholder. For more
information, please visit our website at www.myovant.com.
Follow @Myovant on Twitter and LinkedIn.
Investor Contact:Frank KarbePresident and Chief
Financial OfficerMyovant Sciences, Inc.investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024